Accounts Receivable, after Allowance for Credit Loss, Current in USD of BriaCell Therapeutics Corp. from Q2 2021 to Q1 2024

Taxonomy & unit
us-gaap: USD
Description
Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.
Summary
BriaCell Therapeutics Corp. quarterly Accounts Receivable, after Allowance for Credit Loss, Current history and change rate from Q2 2021 to Q1 2024.
  • BriaCell Therapeutics Corp. Accounts Receivable, after Allowance for Credit Loss, Current for the quarter ending 30 Apr 2024 was $15,233, a 2.3% increase year-over-year.
Source SEC data
View on sec.gov
Accounts Receivable, after Allowance for Credit Loss, Current, Quarterly (USD)
Accounts Receivable, after Allowance for Credit Loss, Current, YoY Quarterly Change (%)

BriaCell Therapeutics Corp. Quarterly Accounts Receivable, after Allowance for Credit Loss, Current (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q1 2024 $15,233 +$337 +2.3% 30 Apr 2024 10-Q 14 Jun 2024 2024 Q3
Q4 2023 $30,145 +$21,217 +238% 31 Jan 2024 10-Q 18 Mar 2024 2024 Q2
Q3 2023 $21,410 -$8,288 -28% 31 Oct 2023 10-Q 14 Dec 2023 2024 Q1
Q2 2023 $18,873 -$5,230 -22% 31 Jul 2023 10-Q 14 Jun 2024 2024 Q3
Q1 2023 $14,896 30 Apr 2023 10-Q 14 Jun 2023 2023 Q3
Q4 2022 $8,928 31 Jan 2023 10-Q 16 Mar 2023 2023 Q2
Q3 2022 $29,698 31 Oct 2022 10-Q 14 Dec 2022 2023 Q1
Q2 2022 $24,103 +$11,529 +92% 31 Jul 2022 10-K 25 Oct 2023 2023 FY
Q2 2021 $12,574 31 Jul 2021 10-K 28 Oct 2022 2022 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.